| abstract |
The present invention relates to pharmaceutical compositions of 6- (6-hydroxymethyl-pyrimidin-4-yloxy) -naphthalene-1-carboxylic acid (3-trifluoromethyl-phenyl) -amide, in particular dysregulation of VEFG / 6- (6-hydroxymethyl-pyrimidin-4-yloxy) -naphthalene-1-carboxylic acid (3- in therapeutic use for indications with overexpression, (neo) -angiogenesis and VEGF induced angiogenesis Of the composition of trifluoromethyl-phenyl) -amide and 6- (6-hydroxymethyl-pyrimidin-4-yloxy) -naphthalene-1-carboxylic acid (3-trifluoromethyl-phenyl) -amide Uses, and methods of preparing such compositions, the invention also relates to 6- (6-hydroxymethyl-pyrimidin-4-yloxy) -naphthalene-1-carboxylic acid (3-trifluoromethyl-phenyl Specific forms of) -amides, and the preparation and use of such forms. The invention also relates to a new process for preparing 6- (6-hydroxymethyl-pyrimidin-4-yloxy) -naphthalene-1-carboxylic acid (3-trifluoromethyl-phenyl) -amide. |